EGFR P848L

CI-VAR-00003415Explore in graph →NP_005219.2:p.Pro848LeuNM_005228.4:c.2543C>TClinVar 45282 CIViC 1465 rs148934350

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
EGFR P848L	Erlotinib	Predictive	D	Supports Resistance	—	submitted	EID4281 In an in vitro study, a MCF-7 cell line expressing EGFR P848L demonstrated reduced sensitivity to erlotinib treatment compared to MCF-7 cells expressing EGFR L858R (a known sensitizing mutation to EGF… (full text at CIViC) PMID 17877814 · de Gunst et al., 2007 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
45282	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications	1	Lung carcinoma; EGFR-related lung cancer; Hereditary cancer-predisposing syndrome; Lung cancer	germline/somatic	10	Jan 28, 2026	clinvar